The Parker Institute sponsors several immunotherapeutic clinical trials. These are the PICI trials currently open for accrual at MSKCC.

• PICI0044/ NCT04787991
  A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)
• NCT04374461
  Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients with Refractory COVID-19 Infection
• NCT04426201
  Recombinant Human Interleukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic Patients with COVID-19 Infection (COVID)
• PICI0025
  An Exploratory Study of Nivolumab with or without Ipilimumab Immunotherapy According to Tumor CD8 Level in Patients with Advanced Cancer
• PICI0001
  A Phase II Study of Immunotherapy: Ipilimumab Alone or with Nivolumab in Patients Whose Melanoma Continues to Grow Despite Nivolumab or Pembrolizumab
• PICI0002
  A Phase IB/II Study of APX005M Immunotherapy plus Gemcitabine and nab-Paclitaxel, with or without Nivolumab, in Patients with Previously Untreated Metastatic Pancreatic Cancer
• PICI0014
  Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW)
• PICI0033
  Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)